The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch...
Many investors pay attention to mid-cap stocks because they have established business models and expansive market opportunities. However, their paths to beco...
In a move that signals a decisive pivot for the biotechnology giant, Biogen Inc. (NASDAQ: BIIB) announced on March 31, 2026, that it has entered into a definitive agreement to acquire Apellis Pharmaceuticals (NASDAQ: APLS) for approximately $5.6 billion. The acquisition, which centers on Apellis' pioneering therapies targeting the
As of April 3, 2026, the American equity market is witnessing a historic "Great Rotation" that many analysts believe could define the latter half of the decade. For the first time in over a quarter-century, the valuation gap between the S&P 500 (INDEXSP:INX) and the Russell 2000 (INDEXRUSSELL:
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...
What Happened? A number of stocks fell in the afternoon session after reports revealed that the US may impose up to 100% tariffs on imports of branded and pa...
In a move that has sent shockwaves through the biotechnology sector, Apellis Pharmaceuticals (Nasdaq: APLS) witnessed an extraordinary 135.7% surge in its share price on March 31, 2026. The massive technical breakout followed the announcement that Biogen (Nasdaq: BIIB) has entered into a definitive agreement to acquire the leader
In a move that signals a decisive shift away from its traditional focus on neuroscience, Biogen (NASDAQ: BIIB) announced today, March 31, 2026, that it has entered into a definitive agreement to acquire Apellis Pharmaceuticals (NASDAQ: APLS) for approximately $5.6 billion in cash. The deal, valued at $41 per
Date: March 31, 2026 Introduction In the spring of 2026, the global pharmaceutical landscape is increasingly defined by the gravitational pull of a single entity: Eli Lilly and Company (NYSE: LLY). Once a steady mid-tier giant known for insulin and antidepressants, Lilly has transformed into the world’s first trillion-dollar healthcare titan. Today’s announcement—a definitive $6.3 [...]
On March 25, 2026, the landscape of neurodegenerative medicine underwent a seismic shift. The U.S. Food and Drug Administration (FDA) granted accelerated approval to Denali Therapeutics (NASDAQ: DNLI) for its lead asset, AVLAYAH™ (tividenofusp alfa-eknm). This represents more than just a new treatment for Hunter Syndrome; it marks the first time in medical history that [...]
As of March 10, 2026, the biopharmaceutical sector is witnessing a historic realignment in the neurology space, spearheaded by the Canadian-born clinical powerhouse Xenon Pharmaceuticals Inc. (Nasdaq: XENE). Long a favorite of biotech specialists for its deep expertise in ion-channel biology, Xenon has officially transitioned from a "high-potential" R&D firm to a "pre-commercial" titan following [...]
Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics earnings season. Over the next ...
